Buckingham Asset Management buys $970,524 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Buckingham Asset Management scooped up 45 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 14,579 shares of AbbVie Inc which is valued at $970,524.AbbVie Inc makes up approximately 0.32% of Buckingham Asset Management’s portfolio.

Other Hedge Funds, Including , Mcrae Capital Management Inc added ABBV to its portfolio by purchasing 5,242 company shares during the most recent quarter which is valued at $348,960. AbbVie Inc makes up approx 0.16% of Mcrae Capital Management Inc’s portfolio.Sequoia Financial Advisors reduced its stake in ABBV by selling 273 shares or 7.71% in the most recent quarter. The Hedge Fund company now holds 3,267 shares of ABBV which is valued at $216,373. AbbVie Inc makes up approx 0.06% of Sequoia Financial Advisors’s portfolio.Meag Munich Ergo Kapitalanlagegesellschaft Mbh boosted its stake in ABBV in the latest quarter, The investment management firm added 173,542 additional shares and now holds a total of 424,466 shares of AbbVie Inc which is valued at $28,112,383. AbbVie Inc makes up approx 2.46% of Meag Munich Ergo Kapitalanlagegesellschaft Mbh’s portfolio.Miller Howard Investments Inc Ny reduced its stake in ABBV by selling 84,988 shares or 4.37% in the most recent quarter. The Hedge Fund company now holds 1,860,184 shares of ABBV which is valued at $118,698,341. AbbVie Inc makes up approx 2.07% of Miller Howard Investments Inc Ny’s portfolio.

AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *